Atlanta, GA – According to filings with the U.S. Securities and Exchange Commission, Antios Therapeutics is raising $85,999,993.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Gregory Mayes played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Antios Therapeutics
Antios Therapeutics is a clinical-stage biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its lead oral drug candidate for a potentially curative treatment of HBV infections. Founded in 2018, Antios Therapeutics is a biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. Our lead therapeutic candidate, ATI-2173, is a first-in-class Active Site Polymerase Inhibitor Nucleotide (ASPIN) that is in clinical development as the backbone of an oral, once-daily potentially curative treatment for HBV. To-date, we have completed extensive pre-clinical work, as well as Phase 1 studies in both healthy volunteers and HBV-infected individuals. A Phase 2a study of ATI-2173 in HBV-infected and HBV/Hepatitis delta virus (HDV) co-infected individuals is currently underway.

To learn more about Antios Therapeutics, visit http://www.antiostherapeutics.com/

Contact:
Gregory Mayes, Chief Executive Officer
404-368-1554
gmayes@antiostherapeutics.com
https://www.linkedin.com/in/greg-mayes-82467911/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved